Loading clinical trials...
Loading clinical trials...
This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hebei Yanda Hospital
Collaborators
NCT06763965 · Recurrent High-grade Glioma
NCT05737212 · Recurrent High-grade Glioma, Recurrent Glioblastoma, and more
NCT04588987 · Neoadjuvant Therapy, Carilizumab, and more
Beijing Tiantan Hospital
Beijing, Beijing Municipality
Hebei Yanda Hospital
Sanhe, Hebei
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions